TScan Therapeutics (TCRX) Competitors $1.55 -0.19 (-10.92%) Closing price 04:00 PM EasternExtended Trading$1.59 +0.04 (+2.84%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends TCRX vs. SNDL, TRDA, SLDB, ARCT, ORKA, RVNC, MREO, TRML, GLUE, and HUMAShould you be buying TScan Therapeutics stock or one of its competitors? The main competitors of TScan Therapeutics include SNDL (SNDL), Entrada Therapeutics (TRDA), Solid Biosciences (SLDB), Arcturus Therapeutics (ARCT), Oruka Therapeutics (ORKA), Revance Therapeutics (RVNC), Mereo BioPharma Group (MREO), Tourmaline Bio (TRML), Monte Rosa Therapeutics (GLUE), and Humacyte (HUMA). These companies are all part of the "pharmaceutical products" industry. TScan Therapeutics vs. SNDL Entrada Therapeutics Solid Biosciences Arcturus Therapeutics Oruka Therapeutics Revance Therapeutics Mereo BioPharma Group Tourmaline Bio Monte Rosa Therapeutics Humacyte TScan Therapeutics (NASDAQ:TCRX) and SNDL (NASDAQ:SNDL) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, community ranking, profitability, analyst recommendations, media sentiment, earnings and institutional ownership. Is TCRX or SNDL more profitable? SNDL has a net margin of -12.11% compared to TScan Therapeutics' net margin of -1,188.88%. SNDL's return on equity of -8.27% beat TScan Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets TScan Therapeutics-1,188.88% -58.72% -36.02% SNDL -12.11%-8.27%-6.96% Does the media favor TCRX or SNDL? In the previous week, TScan Therapeutics had 8 more articles in the media than SNDL. MarketBeat recorded 14 mentions for TScan Therapeutics and 6 mentions for SNDL. SNDL's average media sentiment score of 0.70 beat TScan Therapeutics' score of -0.20 indicating that SNDL is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TScan Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral SNDL 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings & valuation, TCRX or SNDL? TScan Therapeutics has higher earnings, but lower revenue than SNDL. SNDL is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTScan Therapeutics$2.82M31.15-$89.22M-$1.15-1.35SNDL$911.22M0.45-$127.91M-$0.31-5.00 Do insiders and institutionals hold more shares of TCRX or SNDL? 82.8% of TScan Therapeutics shares are held by institutional investors. 2.8% of TScan Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more volatility & risk, TCRX or SNDL? TScan Therapeutics has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500. Comparatively, SNDL has a beta of 3.39, suggesting that its stock price is 239% more volatile than the S&P 500. Do analysts recommend TCRX or SNDL? TScan Therapeutics presently has a consensus target price of $9.33, indicating a potential upside of 502.15%. SNDL has a consensus target price of $3.25, indicating a potential upside of 109.68%. Given TScan Therapeutics' higher possible upside, equities research analysts plainly believe TScan Therapeutics is more favorable than SNDL.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TScan Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00SNDL 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor TCRX or SNDL? SNDL received 101 more outperform votes than TScan Therapeutics when rated by MarketBeat users. However, 83.33% of users gave TScan Therapeutics an outperform vote while only 72.31% of users gave SNDL an outperform vote. CompanyUnderperformOutperformTScan TherapeuticsOutperform Votes4083.33% Underperform Votes816.67%SNDLOutperform Votes14172.31% Underperform Votes5427.69% SummaryTScan Therapeutics beats SNDL on 9 of the 17 factors compared between the two stocks. Remove Ads Get TScan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TCRX vs. The Competition Export to ExcelMetricTScan TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$87.72M$3.11B$5.73B$8.15BDividend YieldN/A1.46%4.41%4.09%P/E Ratio-1.4628.6224.0519.22Price / Sales31.15436.44416.1090.03Price / CashN/A168.6838.0534.64Price / Book0.493.456.934.38Net Income-$89.22M-$71.72M$3.18B$246.90M7 Day Performance-16.67%1.95%10.25%4.31%1 Month Performance-24.39%-12.26%0.89%-7.71%1 Year Performance-78.23%-21.54%14.64%5.72% TScan Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TCRXTScan Therapeutics2.6509 of 5 stars$1.55-10.9%$9.33+502.2%-75.6%$87.72M$2.82M-1.46100Analyst ForecastHigh Trading VolumeSNDLSNDL2.9589 of 5 stars$1.51-3.2%$3.25+115.2%+7.9%$396.79M$911.22M-4.872,516Upcoming EarningsNews CoverageTRDAEntrada Therapeutics2.7288 of 5 stars$10.50-2.5%$25.67+144.4%-15.4%$394.75M$210.78M6.60110SLDBSolid Biosciences3.6563 of 5 stars$5.09-6.1%$15.80+210.4%-61.1%$388.46M$8.09M-1.67100ARCTArcturus Therapeutics3.2257 of 5 stars$14.29-1.8%$59.20+314.3%-61.2%$387.07M$138.39M-6.44180Analyst RevisionORKAOruka Therapeutics3.0234 of 5 stars$10.94+4.6%$39.86+264.3%N/A$382.89MN/A-1.75N/ARVNCRevance Therapeutics2.039 of 5 stars$3.65flat$8.39+129.7%N/A$381.02M$234.04M-1.89500MREOMereo BioPharma Group2.8879 of 5 stars$2.45-1.6%$7.83+219.7%-15.8%$380.11M$1M0.0040TRMLTourmaline Bio1.5496 of 5 stars$14.65+1.9%$52.86+260.8%-56.5%$375.67MN/A-5.2044Earnings ReportUpcoming EarningsAnalyst ForecastGLUEMonte Rosa Therapeutics1.856 of 5 stars$6.03-5.6%$14.00+132.2%-2.2%$370.47M$14.98M-3.3090Upcoming EarningsAnalyst RevisionHUMAHumacyte1.8938 of 5 stars$2.90-6.1%$13.71+372.9%-6.2%$364.99M$1.57M-2.16150 Remove Ads Related Companies and Tools Related Companies SNDL Competitors Entrada Therapeutics Competitors Solid Biosciences Competitors Arcturus Therapeutics Competitors Oruka Therapeutics Competitors Revance Therapeutics Competitors Mereo BioPharma Group Competitors Tourmaline Bio Competitors Monte Rosa Therapeutics Competitors Humacyte Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TCRX) was last updated on 3/17/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TScan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TScan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
